fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Next generation CAR T cells for lymphoma and beyond

Written by | 10 Sep 2019

The first CAR T-cell treatment was administered in 2010 but the field has developed rapidly since then and in the first quarter of 2018 more than 100 trials… read more.

Perspectives on Hodgkin Lymphoma

Written by | 10 Sep 2019

Checkmate 205, Cohort D. The results of the two-year, post-treatment follow-up of the Checkmate 205, Cohort D study group suggests that nivolumab followed by nivolumab + AVD could… read more.

Improvements still needed with front-line treatment

Written by | 10 Sep 2019

Although early stage HL patients have an outstanding result, according to Prof Stephen Ansell (Rochester, USA), he argues that those with stage 3 and 4 disease don’t do nearly as… read more.

Treating HL in the new millennium

Written by | 10 Sep 2019

Prof Peter Johnson (Southampton, UK) discusses where there is consensus and controversy in the management of HL in 2019, as well as talking about the key takeaways from his… read more.

Double hit lymphoma – so what?

Written by | 10 Sep 2019

Professor Andrew Davies (Southampton, UK) discussed his presentation on double hit lymphoma. Written by Christine Clark.

Plenary – Lenalidomide plus RCHOP in DLBCL

Written by | 10 Sep 2019

Prof Andy Davies (Southampton, UK) discusses 2 important abstracts presented in the plenary session at ICML looking at whether there was a benefit to adding lenalidomide to RCHOP for… read more.

Hot topics in lymphoma for 2019

Written by | 10 Sep 2019

To give you a flavour of key recent advances in the management of lymphoma we asked in this video a group of experts at ICML this summer what… read more.

Integrating CAR T-Cell therapy into the treatment of myeloma

Written by | 7 May 2019

Professor Julie Vose (Nebraska, USA) updates us on the current status of BCMA CAR T-cell therapy.

What are the opportunities for genomic-driven change in lymphoma?

Written by | 3 May 2019

Dr Chris Fox (Nottingham, UK) highlights another presentation from Lymphoma SIG around the opportunities for genomic-driven change in lymphoma.

Highlights from ASH 2018

Written by | 14 Feb 2019

As usual, ASH provided lots of exciting updates in the management of lymphoma. One particularly interesting study from which data was presented at ASH was the ECHELON-2 study,… read more.

ASH 2018: Advances in the management of peripheral T-cell lymphoma

Written by | 5 Feb 2019

Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of lymphoid malignancies that often fails to respond to standard of care treatment,1-3 and the need for new therapies is… read more.

ASH 2018: Novel agents in combination for relapsed/refractory Hodgkin’s lymphoma: the ECOG-ACRIN E4412 study

Written by | 14 Jan 2019

Article written by Maria Dalby. Interviews by Hannah Chatfield. Immune checkpoints such as CTLA-4 and PD-1 are known to play a vital part in anti-tumour T-cell function in… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.